A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors

Recruiting

Phase 1

A Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid TumorsA Study Evaluating AB248 Alone or in Combination with Pembrolizumab in Adult Patients with Solid Tumors

Sponsor:

Asher Biotherapeutics, Inc.

Code:

NCT05653882

Conditions

Solid Tumor

Non Small Cell Lung Cancer

Melanoma

Squamous Cell Carcinoma of Head and Neck

Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

etakafusp alfa (AB248)

pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-01. This information was provided to ClinicalTrials.gov by Asher Biotherapeutics, Inc. on 2025-03-25.